Skip to main content
. 2020 Jul 18;11(7):547. doi: 10.1038/s41419-020-02753-x

Fig. 4. Knockdown of NCAPG sensitizes resistant HER2+ BC cells to trastuzumab in vitro.

Fig. 4

a Representative micrographs (left) and quantification (right) of colony formation assays for trastuzumab-resistant SKBR3 and BT474 cell lines, SKBR3/TR and BT474/TR, with or without NCAPG knockdown under treatment with trastuzumab (10 μg/mL). b Cell viability measured by MTT assay. c Flow cytometry analysis of apoptosis by Annexin V-FITC/PI staining (left) and histograms (right), indicating the percentage of Annexin V+ cells. d Representative images (left) and quantification (right) of fluorescence micrographs TUNEL-stained cells in the indicated cells treated with trastuzumab (10 μg/mL). Scr Scramble; sh shRNA. Error bar represents the mean ± SD of three independent experiments. *P < 0.05; **P < 0.01; ***P < 0.001.